Weighing the Evidence: Blood Glucose Levels Decrease with Insulin Sensitizer Despite Weight Increase


By: Jan Chait

A shift in fat distribution from visceral (the internal abdominal area) to subcutaneous (under the skin) could be the reason the insulin sensitizer Actos (pioglitazone) helps to lower blood glucose levels in people with insulin resistance.

Researchers from the University of Texas studied nine people with type 2 diabetes who took Actos for 16 weeks.

Despite an average weight gain of nearly 7 pounds and an increase in total fat mass during that time, fasting blood glucose levels fell from an average of 179 mg/dl to 140 mg/dl, and A1C levels dropped from 8.6% to 7.2%. Fat distribution was evaluated with magnetic resonance imaging (MRI), which showed a decreased ratio of visceral to subcutaneous fat during the study.

-Journal of Clinical Endocrinology & Metabolism, June 2002



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.